BioCatalyst

JDQ443, trametinib, Ribociclib, cetuximab — catalyst calendar

1 verified catalyst event(s) referencing JDQ443, trametinib, Ribociclib, cetuximab, each linked to its official source. Verified as of 2026-06-22.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-09-30
in 3mo
ESTIMATED
 READOUT
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors
Phase 1/2 · KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung
 NVS NOVARTIS AG JDQ443, trametinib, Ribociclib, cetuxima ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.